14. Equitable Access
[This Clause 14 is based on CEPI’s expectation that most of the vaccines it helps to develop will not be profit–making, particularly in low to middle income countries (“LMICs”) in affected areas where purchasing power is limited. It is CEPI’s policy that access to these vaccines will be provided at a cost to LMICs that is fair both to the populations who need them and to CEPI’s awardees who develop products.]
14.1 Equitable Access. CEPI is committed to achieving equitable access to the outputs of all CEPI–supported programmes including access to all Project Results, pursuant to CEPI’s “Equitable Access” Policy. Equitable Access to epidemic vaccines in the context of an Outbreak means that appropriate vaccines are first available to populations when and where they are needed to end an Outbreak or curtail an epidemic, regardless of ability to pay. CEPI is also committed to supporting Equitable Access so that the economics are sustainable to the manufacturer.
14.2 The Awardee will: to the extent that Awardee commercializes Product which utilizes or otherwise benefits from, whether directly or indirectly, any Project Result, the distribution of that product in LMICs will be consistent with CEPI’s Equitable Access Policy and Cost Guidance Policy, as well as with The Bill & Melinda Gates Foundation’s approach to determining appropriate product costs.